bezafibrate has been researched along with fenofibrate in 135 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (11.85) | 18.7374 |
| 1990's | 34 (25.19) | 18.2507 |
| 2000's | 46 (34.07) | 29.6817 |
| 2010's | 35 (25.93) | 24.3611 |
| 2020's | 4 (2.96) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ide, T; Miyachi, H; Murakami, K; Nomura, M; Suzuki, M; Tanase, T; Tsunoda, M; Uchiki, H | 1 |
| Henke, BR | 1 |
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 1 |
| Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
| Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF | 1 |
| Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Doddareddy, MR; Gavande, N; Groundwater, PW; Hibbs, DE; Matin, A; Nammi, S; Roubin, RH | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Bosca, F; Fortea, JM; Janes, C; Latasa, JM; Millan, F; Miranda, MA; Serrano, G | 1 |
| Dorić, M; Gligora, M | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Muros, MA; Prados, J; Vélez, C | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Fernández, JE; González, FJ; Linares, A; Muros, MA; Vélez, C | 1 |
| Schwandt, P | 1 |
| Frishman, WH; Kahn, S; Zimetbaum, P | 1 |
| Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
| Arsenio, L; Rossi, A | 1 |
| Krause, BR; Newton, RS | 1 |
| Bastow, MD; Durrington, PN; Ishola, M | 1 |
| Palmer, RH | 1 |
| Hunninghake, DB; Peters, JR | 1 |
| Grundy, SM; Vega, GL | 1 |
| Sermukslis, B; Smud, R | 1 |
| Leiss, O; Meyer-Krahmer, K; von Bergmann, K | 1 |
| Acuña, AM; Gladstein, J; Tesone, PA | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Sznajderman, M | 1 |
| Leiss, O; von Bergmann, K | 1 |
| Harvengt, C; Heller, F | 1 |
| Canzler, H | 1 |
| Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
| Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W | 1 |
| Duncan, A; Murphy, MJ; O'Reilly, DS; Packard, CJ; Vallance, BD | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Alvarez, L; Aránega, A; Aránega, AE; Gonzalez, AR; Melguizo, C; Muros, MA; Vélez, C | 1 |
| Schonfeld, G | 1 |
| Dujovne, CA; Lozada, A | 1 |
| Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 2 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Bismuth, J; Bonne, J; Gharbi-Chihi, J; Teboul, M; Torresani, J | 1 |
| Shepherd, J | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM | 1 |
| Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME | 1 |
| Aranega, A; Aranega, AE; Gonzalez, FJ; Melguizo, C; Prados, JC; Velez, MC | 1 |
| Diemer, S; Eberlein-König, B; Przybilla, B | 1 |
| Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Feussner, G; Kurth, B; Lohrmann, J | 1 |
| Sinzinger, H | 1 |
| Fekete, T; Gregus, Z; Gyurasics, A; Halászi, E; Klaassen, CD | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Wallace, KB; Zhou, S | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Bellamy, FD; Chaput, E; Edgar, AD; Maubrou-Sanchez, D | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| Soska, V | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C | 1 |
| Bargman, JM; Lipscombe, J | 1 |
| Knight, BL; Puckey, LH | 1 |
| Yamada, N | 1 |
| Fujii, H; Hirano, F; Hirano, Y; Makino, I | 1 |
| Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V | 1 |
| Bellido, A; Cabrero, A; Laguna, JC; Novell, F; Rodríguez, C; Roglans, N; Ros, E; Zambón, D | 1 |
| Hayakawa, T; Inotsume, N; Sekiguchi, M; Sekiya, S; Shimoyama, K | 1 |
| Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Hirano, F; Kobayashi, A; Makino, I | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Alegret, M; Cabrero, A; Carrera, MV; Cubero, M; Jové, M; Laguna, JC; Llaverías, G; Planavila, A; Sánchez, R | 1 |
| Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Alegret, M; Laguna, JC; Novell, F; Roglans, N; Ros, E; Sánchez, RM; Vázquez-Carrera, M; Zambón, D | 1 |
| Goya, K; Kasayama, S; Kawase, I; Kitamura, T; Kouhara, H; Kurebayashi, S; Saito, H; Sumitani, S; Xu, X; Yamamoto, H | 1 |
| Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, M; Neuvonen, PJ | 1 |
| Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Asai, T; Cao, X; Hirai, T; Kambe, F; Murakami, H; Murakami, R; Murohara, T; Numaguchi, Y; Okumura, K; Seo, H; Takahashi, R | 1 |
| Duriez, P; Fruchart, JC | 1 |
| Chinetti, G; Fontaine, C; Fruchart, JC; Robillard, R; Staels, B | 1 |
| Caguyong, MJ; Cornwell, PD; Dai, X; De Souza, AT; Ulrich, RG | 1 |
| Buckley, KA; Chan, BY; Dillon, JP; Fraser, WD; Gallagher, JA; Gartland, A; Wilson, PJ | 1 |
| Blann, E; Collins, J; Dial, S; Dragan, YP; Fan, XH; Fang, H; Guo, L; Mehta, K; Shi, L; Tong, W; Wong, A | 1 |
| Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Fujita, K; Funahashi, T; Hibuse, T; Hiuge, A; Kihara, S; Kumada, M; Maeda, N; Matas, Z; Motro, M; Nishizawa, H; Shimomura, I; Tanne, D; Tenenbaum, A | 1 |
| Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF | 1 |
| Isidori, M; Nardelli, A; Parrella, A; Pascarella, L; Rubino, M | 1 |
| Berneis, K; Rizzo, M | 1 |
| Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S | 1 |
| Bassendine, MF; Jones, DE; Newton, J; Walker, LJ | 1 |
| Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
| Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
| Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL | 1 |
| Bordet, R; Destée, A; Duhamel, A; Kreisler, A; Vanbesien-Mailliot, C | 1 |
| Hattori, S; Hattori, Y; Inoue, T; Kasai, K; Tomizawa, A | 1 |
| Bloomgarden, ZT; Drexler, A | 1 |
| Inazu, A; Ito, N; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Noguchi, T; Nohara, A; Oka, R; Sugihara, M; Tada, H; Takata, M; Yagi, K; Yamaaki, N; Yamagishi, M | 1 |
| Chan, DC | 1 |
| Kawashima, Y; Kudo, N; Mitsumoto, A; Okada, H; Sakamoto, T; Sunaga, K; Tsuda, T; Yamazaki, T | 1 |
| Aruanno, A; Buonomo, A; Nucera, E; Pecora, V; Schiavino, D | 1 |
| Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kawamura, T; Matsumura, K; Matsushita, T; Miyamoto, L; Nakamoto, A; Nemoto, H; Taoka, C; Tsuchiya, K | 1 |
| Ikeda, E; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Tanaka, S; Wakabayashi, M; Yamazaki, T | 1 |
| Huang, H; Kier, AB; Landrock, D; Martin, GG; McIntosh, AL; Petrescu, AD; Schroeder, F; Storey, SM | 1 |
| Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
| Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
| Dohmen, K; Haruno, M; Tanaka, H | 1 |
| Oliveira, HC; Patrício, PR; Raposo, HF; Simões, MC | 1 |
| Blednov, YA; Ferguson, LB; Harris, RA; Most, D | 1 |
| Benavidez, JM; Black, M; Blednov, YA; Edenberg, HJ; Ferguson, LB; Foroud, T; Goate, AM; Harris, RA; Hesselbrock, V; Schoenhard, GL; Wetherill, L | 1 |
| Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
| Czul, F; Levy, C | 1 |
| Heo, TH; Hong, M; Jun, HS; Kim, SJ; Lee, HK; Lee, YS; Song, KD; Yi, S | 1 |
| Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S | 1 |
| Du, L; Liu, M; Ma, Y; Tang, H; Yan, L | 1 |
| Strassburg, CP | 1 |
| Aleandri, S; Kuentz, M; Niederquell, A; Schönenberger, M | 1 |
| Ben Belkacem, K; Chazouillères, O; Corpechot, C; Gaouar, F; Housset, C; Kemgang Fankem, AD; Lemoinne, S; Pares, A; Poupon, R; Reig, A | 1 |
| Bahar, R; Bowlus, CL; Liu, CH; Wong, KA | 1 |
| Hirschfield, GM; Webb, GJ | 1 |
| Chazouillères, O; Corpechot, C; Lemoinne, S; Rousseau, A | 1 |
| Chang, Y; Cho, EJ; Chung, SW; Kim, MA; Kim, SW; Kim, YJ; Lee, HY; Lee, JH; Lee, YB; Leem, G; Park, JY; Yoon, JH; Yoon, JS; Yu, SJ | 1 |
| Chen, J; Li, C; Peijnenburg, WJGM; Qin, W; Qu, J; Zhang, YN; Zhao, J; Zhao, Y; Zhou, Y | 1 |
| Albillos, A; Álvarez-Navascués, C; Andrade, RJ; Arencibia, A; Berenguer, M; Casado, M; Chahri, N; De la Cruz, G; Diago, M; Estevez, P; Fábrega, E; Fernandez-Bonilla, E; Fernández-Rodriguez, CM; Ferre-Aracil, C; Gallego-Moya, A; Gómez-Camarero, J; Gómez-Domínguez, E; González-Santiago, JM; Hernández-Guerra, M; Hijona, L; Horta, D; Molina, E; Morillas, RM; Parés, A; Pérez-Medrano, IM; Reig, A; Romero-Gomez, M; Sala, M; Suárez, F; Vargas, V; Vergara, M | 1 |
| Chen, Y; Mu, T; Shao, Q; Tong, N; Yang, X; Zhang, X; Zhang, Y; Zhou, Y | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y | 1 |
26 review(s) available for bezafibrate and fenofibrate
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen.
Topics: Aged; Bezafibrate; Cross Reactions; Dermatitis, Photoallergic; Drug Eruptions; Female; Fenofibrate; Humans; Hyperlipidemias; Ketoprofen; Male; Middle Aged; Patch Tests | 1992 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides | 1991 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids | 1987 |
Fibric acids: effects on lipids and lipoprotein metabolism.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides | 1987 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL | 1993 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Present status of fibrates in the treatment of hyperlipoproteinemias].
Topics: Bezafibrate; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents | 1999 |
[Fibrates].
Topics: Bezafibrate; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2002 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Fibrates.
Topics: Animals; Atherosclerosis; Bezafibrate; Cholesterol; Clofibrate; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; PPAR alpha | 2005 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome | 2007 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
Novel Therapies on Primary Biliary Cirrhosis.
Topics: Abatacept; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fenofibrate; Glucocorticoids; Humans; Hypolipidemic Agents; Immunologic Factors; Liver Cirrhosis, Biliary; Mesenchymal Stem Cell Transplantation; Receptors, Cytoplasmic and Nuclear; Rituximab; Ursodeoxycholic Acid; Ustekinumab | 2016 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke | 2016 |
[Modern treatment of primary biliary cholangitis].
Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Multicenter Studies as Topic; PPAR alpha; Pregnancy; Prognosis; Quality of Life; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Treatment Outcome; Ursodeoxycholic Acid | 2018 |
Current Treatment Options for Primary Biliary Cholangitis.
Topics: Alkaline Phosphatase; Bezafibrate; Chenodeoxycholic Acid; Cholagogues and Choleretics; Comorbidity; Drug Therapy, Combination; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Malnutrition; Osteoporosis; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2018 |
Work in Progress: Drugs in Development.
Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Bezafibrate; CD40 Antigens; CD40 Ligand; Chalcones; Chemokine CX3CL1; Chenodeoxycholic Acid; Cholic Acids; Drug Development; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Janus Kinase Inhibitors; Liver Cirrhosis, Biliary; Methylamines; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Thiazepines; Triazoles; Ustekinumab | 2018 |
19 trial(s) available for bezafibrate and fenofibrate
| Article | Year |
|---|---|
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
Topics: Bezafibrate; Clinical Trials as Topic; Dietary Carbohydrates; Double-Blind Method; Fenofibrate; Fructose; Humans; Lipoproteins; Male; Propionates; Triglycerides; Uric Acid | 1988 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Propionates; Triglycerides | 1987 |
Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Propionates; Sex Factors; Triglycerides | 1985 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides | 1984 |
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
Topics: Bezafibrate; Bile; Cholesterol; Female; Fenofibrate; Gallbladder; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Male; Propionates; Triglycerides | 1984 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Topics: Bezafibrate; Fenofibrate; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins | 1997 |
Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
Topics: Adult; Bezafibrate; Chromatography, High Pressure Liquid; Fenofibrate; Folic Acid; Hematinics; Homocysteine; Humans; Hyperhomocysteinemia; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Pyridoxine; Vitamin B 12 | 1999 |
Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
Topics: Acyl-CoA Oxidase; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Carnitine O-Palmitoyltransferase; Cholecystectomy; Cholelithiasis; Cholesterol, HDL; Cholesterol, LDL; DNA Primers; Female; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Male; Middle Aged; Oxidoreductases; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Stearoyl-CoA Desaturase; Transcription Factors; Triglycerides | 2002 |
Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.
Topics: Aged; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2002 |
Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.
Topics: Bezafibrate; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Down-Regulation; Female; Fenofibrate; Gallstones; Gemfibrozil; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
Topics: Adult; Bezafibrate; Blood Glucose; Carbamates; Cross-Over Studies; Delayed-Action Preparations; Drug Interactions; Fenofibrate; Humans; Hypolipidemic Agents; Male; Piperidines; Tablets | 2004 |
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Topics: Adipocytes; Adiponectin; Adult; Analysis of Variance; Animals; Bezafibrate; Cells, Cultured; Disease Models, Animal; Double-Blind Method; Female; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Ligands; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Peroxisome Proliferator-Activated Receptors; Probability; Prospective Studies; RNA, Messenger; Statistics, Nonparametric; Stromal Cells | 2007 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Nephrolithiasis; PPAR alpha; Regression Analysis; Triglycerides; Uric Acid | 2007 |
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adipokines; Adiponectin; Adult; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose Tolerance Test; Humans; Leptin; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Time Factors; Triglycerides | 2011 |
92 other study(ies) available for bezafibrate and fenofibrate
| Article | Year |
|---|---|
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Topics: Animals; CHO Cells; Cholesterol; Cricetinae; Fatty Acids, Nonesterified; Humans; Male; Models, Molecular; Phenylpropionates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transcriptional Activation; Transfection | 2003 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides | 2009 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
Topics: Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Isoflavones; Models, Molecular; Molecular Structure; Peroxisome Proliferator-Activated Receptors; Structure-Activity Relationship | 2013 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Further possibilities of using aryloxycarbonic acid derivatives in clinical practice.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Connective Tissue Diseases; Fenofibrate; Humans; Lymphocyte Activation; Phytohemagglutinins | 1991 |
Effects of fibric acid derivatives on accumulation of actin in myocardiocytes.
Topics: Actins; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardium | 1991 |
Influence of fibric acid derivatives on intermediate filament proteins in myocardiocyte cultures.
Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeletal Proteins; Desmin; Fenofibrate; Gemfibrozil; Heart; In Vitro Techniques; Intermediate Filament Proteins; Myocardium; Vimentin | 1991 |
Fibrates and triglyceride metabolism.
Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
[Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives].
Topics: Adult; Bezafibrate; Drug Evaluation; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Propionates; Time Factors | 1989 |
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates | 1986 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides | 1986 |
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides | 1983 |
[Drug therapy of hypercholesterinemias (author's transl)].
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; Humans; Hypercholesterolemia; Neomycin; Nicotinic Acids; Sitosterols | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides | 1980 |
Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Drug Interactions; Female; Fenofibrate; Humans; Hypolipoproteinemias; Lovastatin; Male; Middle Aged; Probucol; Simvastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Changes in subcellular accumulation of contractile proteins in myocardiocyte cultures: effects of fibric acid derivatives.
Topics: Actinin; Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Contractile Proteins; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Immunoblotting; Myocardial Contraction; Myocardium; Tropomyosin; Troponin; Troponin T | 1993 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Creatinine rise after fibrate therapy in renal graft recipients.
Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney Transplantation; Male | 1993 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Increase of adipose differentiation by hypolipidemic fibrate drugs in Ob 17 preadipocytes: requirement for thyroid hormones.
Topics: Adipose Tissue; Animals; Bezafibrate; Cell Differentiation; Cell Line; Cell Nucleus; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Mice; Mice, Obese; Receptors, Thyroid Hormone; Thyroid Hormones; Thyroxine | 1993 |
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S | 1996 |
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides | 1995 |
Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives.
Topics: Animals; Bezafibrate; Cells, Cultured; Chick Embryo; Cytoskeleton; Densitometry; Electrophoresis, Polyacrylamide Gel; Fenofibrate; Gemfibrozil; Heart; Intermediate Filament Proteins; Myocardium | 1995 |
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region.
Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays | 1996 |
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity | 1996 |
Effects of fibrates on the glycine conjugation of benzoic acid in rats.
Topics: Animal Feed; Animals; Benzoic Acid; Bezafibrate; Fenofibrate; Glycine; Injections, Intraperitoneal; Liver; Male; Rats; Rats, Wistar | 1998 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |
The effect of peroxisome proliferators on mitochondrial bioenergetics.
Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.
Topics: Animals; Bezafibrate; Drug Synergism; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley; Vitamin E | 1999 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea | 2000 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases | 2001 |
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.
Topics: Aged; Amino Acid Substitution; Bezafibrate; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Random Allocation; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Transcription Factors; Triglycerides | 2001 |
Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation.
Topics: Bezafibrate; Chemokine CCL5; Chenodeoxycholic Acid; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Humans; Hypolipidemic Agents; NF-kappa B; Tumor Cells, Cultured | 2002 |
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome | 2002 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2003 |
Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs.
Topics: Bezafibrate; Chemokine CCL5; DNA; Fenofibrate; Gene Expression Regulation; Hepatocytes; Humans; Hypolipidemic Agents; RNA, Messenger; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Topics: Bezafibrate; Cholesterol; Chromans; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins, LDL; Macrophages; Monocytes; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides | 2003 |
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
Topics: Animals; Aorta; Bezafibrate; Cattle; Cells, Cultured; Dactinomycin; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Fenofibrate; Gene Expression Regulation, Enzymologic; Half-Life; Mifepristone; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Bezafibrate; Endothelial Cells; Enzyme Activation; Fenofibrate; Humans; Multienzyme Complexes; Nitric Oxide Synthase Type III; Phosphorylation; PPAR alpha; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Umbilical Veins; Up-Regulation | 2006 |
Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle.
Topics: Animals; Bezafibrate; Fatty Acids; Female; Fenofibrate; Gene Expression Profiling; Glucose; Hypolipidemic Agents; Liver; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; PPAR alpha; Pyrimidines; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazolidinediones; Tretinoin | 2006 |
PPAR agonists modulate human osteoclast formation and activity in vitro.
Topics: Acetates; Apoptosis; Bezafibrate; Bone Resorption; Butyrates; Cells, Cultured; Fenofibrate; Humans; Hypolipidemic Agents; Leukocytes, Mononuclear; Macrophage Colony-Stimulating Factor; Osteoclasts; Peroxisome Proliferator-Activated Receptors; Phenols; Phenoxyacetates; Phenylurea Compounds; RANK Ligand; RNA, Messenger; Thiazolidinediones; Transcription, Genetic | 2007 |
Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; PPAR alpha; Pyrimidines | 2006 |
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra | 2007 |
Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms.
Topics: Aliivibrio fischeri; Animals; Bezafibrate; Chlorophyta; Crustacea; Escherichia coli; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Lethal Dose 50; Mutagenicity Tests; No-Observed-Adverse-Effect Level; Rotifera; Salmonella typhimurium; Toxicity Tests, Acute; Toxicity Tests, Chronic; Ultraviolet Rays; Water Pollutants, Chemical | 2007 |
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles | 2008 |
Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Synergism; Fenofibrate; Humans; Immunoglobulin M; Liver Cirrhosis, Biliary; Prognosis; Ursodeoxycholic Acid | 2009 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrate; Cell Count; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Fenofibrate; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Statistics, Nonparametric; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2010 |
Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation.
Topics: AMP-Activated Protein Kinases; Apoptosis; Bezafibrate; Blotting, Western; Capillaries; Cells, Cultured; Endothelial Cells; Enzyme Activation; Fenofibrate; Glycation End Products, Advanced; Hepatocytes; Humans; Hyperglycemia; Hypolipidemic Agents; I-kappa B Kinase; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type III; PPAR alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Vasculitis | 2011 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents | 2011 |
Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives.
Topics: Adipokines; Bezafibrate; Female; Fenofibrate; Humans; Male; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2011 |
Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats.
Topics: Animals; Bezafibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Fenofibrate; Gene Expression Regulation; Liver; Male; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase | 2012 |
Delayed-type hypersensitivity to fenofibrate.
Topics: Aged; Bezafibrate; Cross Reactions; Drug Hypersensitivity; Dyslipidemias; Emergency Medical Services; Female; Fenofibrate; Humans; Hypersensitivity, Delayed; Hypolipidemic Agents; Skin Tests | 2012 |
Synthesis of highly water-soluble fibrate derivatives via BGLation.
Topics: Animals; Bezafibrate; Clofibrate; Fenofibrate; Hypolipidemic Agents; Male; Rats; Rats, Sprague-Dawley; Solubility; Triglycerides; Water | 2012 |
Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Bezafibrate; Clofibric Acid; Fatty Acids; Fenofibrate; Fibric Acids; Gene Expression; Gene Expression Regulation; Liver; Male; Microsomes, Liver; Phosphatidylcholines; Rats; Rats, Wistar; RNA, Messenger; Stearoyl-CoA Desaturase | 2012 |
High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes.
Topics: Animals; Bezafibrate; Cell Nucleus; Fatty Acid-Binding Proteins; Fatty Acids; Fenofibrate; Glucose; Hepatocytes; Hypolipidemic Agents; Mice; Mice, Mutant Strains; Oxidation-Reduction; PPAR alpha; Signal Transduction; Sweetening Agents | 2013 |
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.
Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; Male; Molecular Targeted Therapy; PPAR alpha; Rats; Rats, Wistar; Triglycerides; Up-Regulation | 2013 |
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger | 2014 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid | 2013 |
Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Topics: Animals; Bezafibrate; Cholesterol Ester Transfer Proteins; Combined Modality Therapy; Corn Oil; Crosses, Genetic; Dietary Supplements; Female; Fenofibrate; Fibric Acids; Fish Oils; Gemfibrozil; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; Mice, Transgenic; Random Allocation; RNA, Messenger; Up-Regulation | 2014 |
PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.
Topics: Alcohol Drinking; Alkanesulfonates; Amygdala; Animals; Bezafibrate; Central Nervous System Agents; Central Nervous System Depressants; Drinking; Drinking Water; Ethanol; Fenofibrate; Gene Expression; Liver; Male; Mice, Inbred C57BL; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Prefrontal Cortex; Taste Perception | 2014 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibrate; Genome-Wide Association Study; Humans; Liver; Male; Mice; Phenylpropionates; Pioglitazone; Polymorphism, Single Nucleotide; PPAR alpha; PPAR gamma; Thiazoles; Thiazolidinediones | 2015 |
Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential.
Topics: Apoptosis; Autophagy; Bezafibrate; Cells, Cultured; Fenofibrate; Gemfibrozil; Humans; Lymphocytes; Membrane Glycoproteins; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Neuronal Ceroid-Lipofuscinoses; Neuroprotective Agents; Oxidative Stress; PPAR alpha | 2016 |
Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo.
Topics: Animals; Bezafibrate; DNA, Viral; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Male; Mice, Inbred BALB C; Models, Animal; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Viral Load; Virus Replication | 2017 |
Temperature-Induced Surface Effects on Drug Nanosuspensions.
Topics: Bezafibrate; Cellulose; Chemistry, Pharmaceutical; Drug Compounding; Drug Liberation; Drug Stability; Drug Storage; Excipients; Fenofibrate; Hypolipidemic Agents; Microscopy, Atomic Force; Nanoparticles; Sodium Dodecyl Sulfate; Solubility; Suspensions; Temperature | 2018 |
Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Drug Therapy, Combination; Female; Fenofibrate; France; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Pruritus; Retrospective Studies; Spain; Ursodeoxycholic Acid; Young Adult | 2018 |
Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response.
Topics: Bezafibrate; Cholangitis; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Ursodeoxycholic Acid | 2019 |
Additional fibrate treatment in UDCA-refractory PBC patients.
Topics: Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Drug Therapy, Combination; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ursodeoxycholic Acid | 2019 |
Trace amounts of fenofibrate acid sensitize the photodegradation of bezafibrate in effluents: Mechanisms, degradation pathways, and toxicity evaluation.
Topics: Bezafibrate; Fenofibrate; Oxidation-Reduction; Photolysis; Singlet Oxygen; Sunlight; Water Pollutants, Chemical | 2019 |
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Topics: Bezafibrate; Chenodeoxycholic Acid; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoprotein Lipase; Mitochondrial Diseases; Mutation | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Topics: Bezafibrate; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Renal Insufficiency; Renal Insufficiency, Chronic; Retrospective Studies | 2023 |